Abivax SA Sponsored ADR (ABVX) AI Stock Analysis

• Market Cap: $424.48M
• Dividend Yield: N/A
• Average Volume (3M): 216.20K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.16
• Revenue Growth: N/A
• EPS Growth: 18.47%
• Country: US
• Employees: 69
• Sector: Healthcare
• Sector Strength: 58
• Industry: Biotechnology
• EPS (TTM): -0.95
• Shares Outstanding: 63,454,205
• 10 Day Avg. Volume: 275,615
• 30 Day Avg. Volume: 216,196
• PEG Ratio: -0.09
• Price to Book (P/B): 19.87
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -6.17
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $35.00
• Price Target Upside: 401.43% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6

• Rating: 48 Neutral
• Price Target: $7.00 ▲(0.29%Upside)

The most significant factor affecting Abivax SA's stock score is its poor financial performance, characterized by ongoing losses and reliance on debt financing. Technical indicators show some short-term positive momentum, but valuation concerns remain due to negative earnings. The absence of positive earnings call insights or corporate events further limits the score.

Positive Factors

Clinical Trials

The Phase 3 ABTECT program with obefazimod is on track, which could lead to a significant stock movement for Abivax due to its current low valuation compared to historical IBD comparisons.

Market Potential

Obefazimod could emerge as a preferred treatment option before JAK inhibitors due to reports of side effects in patients using JAK inhibitors.

Safety Profile

The safety profile of obefazimod has been very good for an IBD medicine, which could enhance its attractiveness in the market.

Negative Factors

Financial Constraints

Abivax has less than 0.8 years of cash left, indicating potential financial constraints.

Financial Strain

Years of cash left is less than 1.0, indicating potential financial strain.

Abivax SA Sponsored ADR Business Overview & Revenue Model

Company Description

Abivax SA Sponsored ADR (ABVX) is a biotechnology company focused on developing therapies for inflammatory diseases, viral infections, and cancer. The company's core products are centered around its proprietary drug candidates, which are designed to modulate the immune response in patients. Abivax operates primarily in the biopharmaceutical sector, leveraging its research and development capabilities to bring innovative solutions to market.

How the Company Makes Money

Abivax makes money through the development and commercialization of its drug candidates. The company generates revenue primarily through strategic partnerships, licensing agreements, and milestone payments from collaborations with other pharmaceutical companies. These partnerships often involve the co-development and co-commercialization of Abivax's drug candidates, providing the company with upfront payments, research funding, and potential royalties on future sales. Additionally, Abivax may receive government grants and research funding to support its R&D activities, which can contribute to its earnings.

Abivax SA Sponsored ADR Financial Statement Overview

Summary

Abivax SA faces significant financial challenges with consistent operational losses and reliance on debt financing. While revenue is growing, profitability remains a concern with high operating losses and negative cash flows. These factors underscore the need for strategic improvements to enhance financial stability.

Income Statement

The company has shown significant revenue growth from the previous year, but still operates at a loss with negative net profit and EBIT margins. The gross profit margin remains stable, yet the high negative EBIT and net income suggest ongoing operational challenges.

Balance Sheet

The company's balance sheet indicates high leverage with a substantial debt-to-equity ratio, but it has managed to maintain a reasonable equity ratio. The return on equity remains negative due to continued losses, suggesting difficulty in generating shareholder value.

Cash Flow

Cash flow from operations is negative, reflecting operational struggles, although there is positive free cash flow growth due to reduced capital expenditures. The company relies heavily on financing activities to manage its cash needs, indicating potential liquidity risks.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
10.79M	4.62M	4.58M	37.00K	63.00K
	Gross Profit
10.79M	4.57M	4.47M	-119.00K	62.00K
	EBIT
-172.98M	-127.38M	-56.65M	-42.56M	-38.01M
	EBITDA
-171.88M	-133.21M	-53.31M	-52.03M	-38.00M
	Net Income Common Stockholders
-176.24M	-147.74M	-69.85M	-41.36M	-37.55M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
144.22M	260.99M	26.95M	60.70M	29.30M
	Total Assets
205.23M	327.06M	73.35M	110.36M	71.30M
	Total Debt
97.36M	55.46M	46.07M	53.45M	33.99M
	Net Debt
-46.86M	-196.48M	19.12M	-7.24M	4.70M
	Total Liabilities
164.64M	131.05M	64.65M	74.75M	53.40M
	Stockholders Equity
40.58M	196.01M	8.70M	35.61M	17.90M
Cash Flow		Free Cash Flow
-154.72M	-100.28M	-28.03M	-47.30M	-30.72M
	Operating Cash Flow
-154.07M	-100.01M	-27.99M	-45.66M	-29.82M
	Investing Cash Flow
15.76M	-10.49M	-513.00K	-1.46M	-575.00K
	Financing Cash Flow
28.21M	340.57M	48.03M	78.51M	49.93M

Abivax SA Sponsored ADR Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 6.98
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ABVX, the sentiment is Negative. The current price of 6.98 is above the 20-day moving average (MA) of 6.71, above the 50-day MA of 6.51, and below the 200-day MA of 8.08, indicating a neutral trend. The MACD of 0.30 indicates Negative momentum. The RSI at 51.40 is Neutral, neither overbought nor oversold. The STOCH value of 38.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ABVX.

Abivax SA Sponsored ADR Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AUTL	55 Neutral	$564.22M	―	-49.97%	―	-14.16%	25.80%
Sector *	54 Neutral	$5.37B	3.26	-45.10%	3.30%	16.81%	0.02%
ABVX	48 Neutral	$424.48M	―	-147.48%	―	―	18.47%
CELC	44 Neutral	$458.56M	―	-115.39%	―	―	-4.14%
ALMS	43 Neutral	$323.43M	―	-247.05%	―	―	-82.41%
ORIC	43 Neutral	$820.71M	―	-48.45%	―	―	7.15%
ERAS	34 Underperform	$419.27M	―	-45.82%	―	―	10.38%